Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urination Disorders 1Urinary Bladder, Overactive 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solifenacin Succinate × Clear all
NCT01777217 2015-01-16

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Advanced Research Network

Phase 4 Terminated
8 enrolled 6 charts
Genitourinary

Urination Disorders, Urinary Bladder, Overactive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡